美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床探讨.docVIP

美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床探讨 　　[摘要] 目的 研究分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。 方法 整群选取2013年3月―2015年3月该院收治的冠心病心力衰竭患者82例，分为两组，每组41例。对照组行常规治疗，观察组给予美托洛尔联合曲美他嗪治疗。对比两组患者治疗效果及心率、左心射血分数（LVEF）。 结果 观察组总有效率为97.56%高于对照组78.05%，差异有统计学意义（P0.01）；治疗后，观察组心率为（90.6±7.2）次/min、LVEF为（50.5±3.5）%，均优于对照组，差异有统计学意义（P0.01）。 结论 美托洛尔联合曲美他嗪治疗冠心病心力衰竭可改善心功能，值得推广。 　　[Abstract] Objective To research and analyze the clinical effect of metoprolol combined with trimetazidine in treatment of coronary heart disease and heart failure. Methods 82 cases of patients with coronary heart disease and heart failure treated from March 2013 to March 2015 were selected and divided into two groups with 41 cases in each， the control group were treated with conventional method， the observation group were treated with metoprolol combined with trimetazidine， the treatment effect ， heart rate and left ventricular ejection fraction（LVEF）of the two groups were compared. Results The total effective rate in the observation group was higher than that in the control group， （97.56% vs 78.05%），and the difference was obvious（P0.01）， after treatment， the heart rate and LVEF were respectively（90.6±7.2）times/min and （50.5±3.5）%， which were better than those in the control group， and the differences were obvious（P0.01）. Conclusion Metoprolol combined with trimetazidine in treatment of coronary heart disease and heart failure can improve the heart function， which is worth promoting. 　　[Key words] Metoprolol； trimetazidine； coronary heart disease and heart failure 　　冠心病主要由体内脂质代谢异常引起的动脉内膜脂质堆积，促使动脉腔狭窄，从而引发心肌缺氧缺血，严重者甚至出现心肌梗死和心力衰竭[1]。研究显示[2]，心力衰竭会造成心输出量显著降低，不能满足患者正常机体需求，给患者生命安全造成严重威胁。该研究整群选取2013年3月―2015年3月该院收治冠心病心力衰竭患者82例分别给予常规治疗和美托洛尔联合曲美他嗪治疗，旨在进一步探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　整群选取2013年3月―2015年3月收治的冠心病心力衰竭患者82例，分为两组，每组41例。对照组男25例，女16例；年龄46～76岁，平均年龄为（61.5±7.1）岁；观察组男23例，女18例；年龄44～75岁，平均年龄为（60.8±7.2）岁。两组临床资料差异无统计学意义（P0.05）。 　　1.2 方法 　　所有患者入院后均给予常规治疗，主要内容包括强心剂、血管紧张素转化酶抑制剂、利尿剂等，治疗3个月为1个疗程；观察组给予美托洛尔联合曲美他嗪治疗冠心病心力衰竭治疗，美托洛尔（国药准